Neoadjuvant chemotherapy regimen extends survival in pancreatic cancer
Neoadjuvant modified FOLFIRINOX alone vs. with hypofractionated radiotherapy demonstrated favorable OS among patients with borderline resectable pancreatic cancer, according to results of a phase 2 trial published in JAMA Oncology.Therefore, modified FOLFIRINOX (leucovorin, 5-FU, irinotecan and oxaliplatin) represents an effective treatment regimen in this patient setting, researchers noted.“Both ASCO clinical practice guidelines and [National Comprehensive Care Network] guidelines recommend the administration of preoperative therapy in anticipation of subsequent pancreatectomy amongRead More